Plain English Summary
Background and study aims
The response of governments during a pandemic are aimed at two main functions: mitigation (to restrict the spread of the virus) and treatment (proper care for those affected). To implement these, a government needs to be able to estimate the effects of any policies introduced. This requires knowledge of how healthcare services are going to manage the situation due to the pandemic, particularly as the pandemic evolves. This is known from data on the levels of infection amongst the population. Ideally, data would be available on the number of new infections, but this is rare if infection is widespread and with no symptoms. Instead data mainly come through screening, recording the number of new hospitalisations or consultations amongst patients with influenza-like illness, perhaps in hospitals or general practices. These datasets contain only a limited amount of information and are susceptible to biases. Therefore, it is preferable to use as many relevant data sources as possible to build an overall picture of the current pandemic situation and predict its future development. A tool is required in the midst of a pandemic to transform these data into meaningful predictions of the burden upon the health service. Real-time modelling involves the use of continuously incoming information to update and revise the estimate of the epidemic features, the future of the pandemic and the assessment of the effectiveness of policies. The difficulty in real-time modelling are: direct data on the transmission process are typically unavailable, and the surveillance data only informs it indirectly. The aim of this study is to improve the real-time modelling approach we developed earlier, whilst remaining on-call to support Public Health England (PHE), who are going to implement this should a pandemic outbreak actually occur.
Who can participate?
No patients or healthy volunteers are involved.
What does the study involve?
Various advancements to the real-time modelling are made to include greater variations between regions, additional data, enhance the efficiency of the algorithm and evaluate the interventions that are likely to be implemented during the pandemic.
What are the possible benefits and risks of participating?
Developing the current approach will result in more accurate estimates and predictions. More importantly, the timeliness of the availability of treatment will also be improved, so that the model is truly operating in real time.
Where is the study run from?
The research is office-based and involves model development and testing of real-time modelling systems. This will take place at the Medical Research Council Biostatistics Unit (MRC-BSU) (UK)
When is the study starting and how long is it expected to run for?
October 2012 to September 2015
Who is funding the study?
National Institute of Health Research (NIHR) (UK)
Who is the main contact?
Dr Daniela De Angelis
daniela.deangelis@mrc-bsu.cam.ac.uk
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
HTA 11/46/03
Study information
Scientific title
Real-time modelling of a pandemic influenza outbreak with two phases: a pre-pandemic phase and an in-pandemic support phase
Acronym
Study hypothesis
The purpose of this project is to advance the real-time modelling approach we developed in response to the 2009 pandemic, whilst remaining 'on call' to support Public Health England (PHE), who are tasked with its implementation should a pandemic outbreak actually occur. This advancement is anticipated to be in the form of:
1. Improving the efficiency with which real-time statistical inferences can be made.
2. Building capacity in terms of the different types and increasing the volume of data that can be used in real-time.
3. Accounting for spatial heterogeneity through the modelling of separate but linked epidemics in spatially disjoint regions (e.g., as currently defined by Strategic Health Authority).
4. Accounting for any likely pandemic mitigation or treatment interventions.
5. To provide a suite of software to implement the above.
6. To support Public Health England (PHE) in providing, in the event of a pandemic, estimates and projections of:
6.1. Age- and region-specific incidence of infection.
6.2. Current and predicted total number of cases.
6.3. Key epidemic parameters, such as the basic reproduction number, R0, and the proportion of infections leading to symptomatic illness.
7. Incorporation of additional data streams on severe events, anticipated as part of the research, will allow also outputs on predicted severe events.
The majority of the research takes place prior to any pandemic outbreak.
Ethics approval
No data is generated as a direct result of this project. No participants are recruited to the study.
Study design
Two phases:
1. A pre-pandemic phase of model development
2. In-pandemic support to PHE's real-time modelling based on data from routine and pandemic surveillance schemes
Primary study design
Observational
Secondary study design
Other
Trial setting
Other
Trial type
Screening
Patient information sheet
N/A
Condition
Pandemic influenza
Intervention
The aim is the enhancement of real-time modelling of infleuenza epidemics. These advancements include:
1. Modifications to the existing model to incorporate greater variation between regions. The current system only allows for the consideration of a single region at a time.
2. Modifications to the existing model to incorporate new or additional data streams, envisaged for future pandemics.
3. Enhancement of algorithmic efficiency. This involves considering state-of-the-art model fitting algorithms, ensuring modelling results are obtained quickly and efficiently.
4. Evaluation of interventions likely to be implemented. Already we can estimate the effect of school closures, but other interventions such as vaccination will be considered.
Intervention type
Other
Phase
Not Applicable
Drug names
Primary outcome measure
To be in a position to provide, in the event of a pandemic influenza outbreak, support to PHE in their task of producing estimates and projections of the epidemic state, and thus contributing valuable input to the public health response.
Secondary outcome measures
The success of the real-time system will additionally be measured through the teams ability to provide:
1. Software to implement a timely and reliable monitoring of an emergent influenza epidemic
2. Scientific publications and dissemination of results, with appropriate acknowledgement of data sources and consultation with data providers
3. Provide valuable input to public health response
Overall trial start date
01/10/2012
Overall trial end date
30/09/2015
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
N/A
Participant type
Patient
Age group
Not Specified
Gender
Not Specified
Target number of participants
0
Participant exclusion criteria
N/A
Recruitment start date
01/10/2012
Recruitment end date
30/09/2015
Locations
Countries of recruitment
United Kingdom
Trial participating centre
MRC Biostatistics Unit
Cambridge
CB2 0SR
United Kingdom
Sponsor information
Organisation
National Institute for Health Research (UK)
Sponsor details
Evaluation
Trials and Studies Coordinating Centre
University of Southampton
Alpha House
Enterprise Road
Southampton
SO16 7NS
United Kingdom
Sponsor type
Government
Website
Funders
Funder type
Government
Funder name
Health Technology Assessment Programme
Alternative name(s)
NIHR Health Technology Assessment Programme, HTA
Funding Body Type
government organisation
Funding Body Subtype
Federal/National Government
Location
United Kingdom
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
Publication list
2017 results in: https://www.ncbi.nlm.nih.gov/pubmed/29058665